Literature DB >> 33726574

Early experience with universal SARS-CoV-2 testing in a New York-based reproductive endocrinology ‎practice.

Julian A Gingold1,2, Sharon Galperin3, Sabrina Fowler3, Michelle Kappy4, Staci Pollack1,2,4, Manvinder Singh1,2,4, Harry Lieman1,2,4, Sangita Jindal1,2,4.   

Abstract

The SARS-CoV-2 pandemic peak around March 2020 led to temporary closures of most fertility clinics. Many clinics reopened but required universal SARS-CoV-2 screening. However, the rate of positive results and the necessity for such testing is unknown. We report here on early results from asingle-center academic NewYork fertility practice utilizing universal SARS-CoV-2 screening. This mixed prospective retrospective cohort included 164 patients who underwent at least one SARS-CoV-2 screening test for fertility treatment between May and July2020. Patients completed 1 to 3 nasopharyngeal SARS-CoV-2 tests per cycle and remained symptom-free to continue fertility treatments. SARS-CoV-2 test results, past results, history of Covid-19 infection, and patient/cycle characteristics were recorded and tabulated through October2020. Outcomes included positive SARS-CoV-2 RNA tests, rate of prior Covid-19 infections, and clinical courses of patients testing positive. Patients underwent 263 cycles entailing 460 total SARS-CoV-2 screening tests. Fifteen patients reported astrong prior clinical history of Covid-19. Six patients experienced apositive SARS-CoV-2 test (2.3% of all cycles). Among 77 cycles (n = 58 patients) entailing one SARS-CoV-2 test, 2 cases (2.6%) were noted. Among 173 cycles (n = 121 patients) entailing two SARS-CoV-2 tests, 4 cycles (2.3%) were noted. Zero (0%) of 13 cycles (n = 13 patients) entailing 3 SARS-CoV-2 tests were positive. All patients were cleared to resume treatment within one month. Overall, anew asymptomatic infection was identified in 2 cycles (0.8%), while 4 of the 6 positive SARS-CoV-2 tests were among patients with aprior history of Covid-19. 3 of 4 also had adocumented prior positive RNA test. Our data suggest that universal SARS-CoV-2 screening among fertility patients is feasible, with an approximately 2% positive rate per cycle among the patients of this study. Most positive patients had aprior remote infection, but their infectiousness while being screened remains unclear.Abbreviations: REI: reproductive endocrinology and infertility; IUI: intrauterine insemination; IVF: in vitro fertilization; sono: sonography; cryo: cryopreservation; FET: frozen embryo transfer.

Entities:  

Keywords:  Covid-19; SARS-CoV2; fertility practice experience; in vitro fertilization; viral screening

Year:  2021        PMID: 33726574     DOI: 10.1080/19396368.2021.1884317

Source DB:  PubMed          Journal:  Syst Biol Reprod Med        ISSN: 1939-6368            Impact factor:   3.061


  2 in total

1.  Rates of COVID-19 infection among in vitro fertilization patients undergoing treatment at a university reproductive health center.

Authors:  Armstrong Abigail; Berger Marisa; Lee Victoria; Tandel Megha; Kwan Lorna; Brennan Kathleen; Al-Safi Zain
Journal:  J Assist Reprod Genet       Date:  2022-07-26       Impact factor: 3.357

2.  The prevalence of SARS-CoV-2 antibodies in triage-negative patients and staff of a fertility setting from lockdown release throughout 2020.

Authors:  Corina Manolea; Andrei Capitanescu; Roxana Borș; Ioana Rugescu; Melihan Bechir; Claudia Mehedintu; Valentin Varlas
Journal:  Hum Reprod Open       Date:  2021-07-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.